The global biologics market is expected to reach $248 billion by 2020, a compound annual growth rate (CAGR) of 9.9%. Driving this growth is the need for a more extensive drug pipeline, attractive targets against challenging diseases, a push to pursue biosimilars, and enabling manufacturing technologies that reduce the cost to produce profitable products.
The global biosimilar market is expected reach $36 billion by year 2022. Keeping this in mind Sujan Biologics is developing the following biosimilars.
